{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Modified+FOLFOX6&page=2", "query": { "intervention": "Modified FOLFOX6", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Modified+FOLFOX6&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-13T18:15:58.778Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00865709", "title": "Study of Modified FOLFOX6 Plus or Minus Sorafenib in Stage IV Metastatic Colorectal Carcinoma (mCRC) Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Colorectal Cancer" ], "interventions": [ { "name": "Sorafenib (Nexavar, BAY43-9006) + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin)", "type": "DRUG" }, { "name": "Matching placebo + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 198, "start_date": "2009-03", "completion_date": "2012-02", "has_results": true, "last_update_posted_date": "2014-12-11", "last_synced_at": "2026-09-13T18:15:58.778Z", "location_count": 5, "location_summary": "Wichita, Kansas • Metairie, Louisiana • Brockton, Massachusetts + 2 more", "locations": [ { "city": "Wichita", "state": "Kansas" }, { "city": "Metairie", "state": "Louisiana" }, { "city": "Brockton", "state": "Massachusetts" }, { "city": "Burlington", "state": "Massachusetts" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00865709" }, { "nct_id": "NCT03193190", "title": "A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "Nab-Paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Cobimetinib", "type": "DRUG" }, { "name": "PEGPH20", "type": "DRUG" }, { "name": "BL-8040", "type": "DRUG" }, { "name": "Selicrelumab", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "RO6874281", "type": "DRUG" }, { "name": "AB928", "type": "DRUG" }, { "name": "Tiragolumab", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 341, "start_date": "2017-07-05", "completion_date": "2025-02-27", "has_results": true, "last_update_posted_date": "2025-11-21", "last_synced_at": "2026-09-13T18:15:58.778Z", "location_count": 12, "location_summary": "Duarte, California • San Francisco, California • New Haven, Connecticut + 8 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03193190" }, { "nct_id": "NCT03439462", "title": "Nab-Sirolimus in Combination With FOLFOX & BEV as 1st Line Therapy in Patients With Advanced or Metastatic Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Colorectal Cancer Metastatic" ], "interventions": [ { "name": "nab-sirolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Aadi Bioscience, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 60, "start_date": "2018-07-01", "completion_date": "2022-08-26", "has_results": true, "last_update_posted_date": "2024-01-02", "last_synced_at": "2026-09-13T18:15:58.778Z", "location_count": 6, "location_summary": "Scottsdale, Arizona • New Orleans, Louisiana • Las Vegas, Nevada + 3 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Las Vegas", "state": "Nevada" }, { "city": "Morristown", "state": "New Jersey" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03439462" }, { "nct_id": "NCT03254394", "title": "Lidocaine for Oxaliplatin-induced Neuropathy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Neuropathy, Painful", "Chemotherapy-induced Peripheral Neuropathy", "Colorectal Cancer" ], "interventions": [ { "name": "Lidocaine Hydrochloride", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "FOLFOX regimen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2017-09-15", "completion_date": "2021-04-01", "has_results": true, "last_update_posted_date": "2022-03-09", "last_synced_at": "2026-09-13T18:15:58.778Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03254394" }, { "nct_id": "NCT04761614", "title": "Riluzole in Combination With mFOLFOX6 and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Colorectal Carcinoma", "Stage IV Colorectal Cancer AJCC v8", "Stage IVA Colorectal Cancer AJCC v8", "Stage IVB Colorectal Cancer AJCC v8", "Stage IVC Colorectal Cancer AJCC v8" ], "interventions": [ { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Riluzole", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Ning Jin", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2021-04-02", "completion_date": "2023-05-06", "has_results": false, "last_update_posted_date": "2025-03-28", "last_synced_at": "2026-09-13T18:15:58.778Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04761614" }, { "nct_id": "NCT06268015", "title": "Botensilimab and Balstilimab Optimization in Colorectal Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "Botensilimab", "type": "DRUG" }, { "name": "Balstilimab", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Panitumumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nicholas DeVito, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2024-11-18", "completion_date": "2028-07", "has_results": false, "last_update_posted_date": "2026-02-05", "last_synced_at": "2026-09-13T18:15:58.778Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT06268015" }, { "nct_id": "NCT03488667", "title": "Perioperative mFOLFOX Plus Pembrolizumab in Gastroesophageal Junction (GEJ) and Stomach Adenocarcinoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastro Esophageal Junction Cancer", "Stomach Cancer", "Adenocarcinoma" ], "interventions": [ { "name": "Neoadjuvant Treatment - mFOLFOX6 & Pembrolizumab", "type": "DRUG" }, { "name": "Adjuvant Treatment - mFOLFOX & Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Kansas Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 40, "start_date": "2018-06-27", "completion_date": "2025-04-30", "has_results": false, "last_update_posted_date": "2023-05-19", "last_synced_at": "2026-09-13T18:15:58.778Z", "location_count": 1, "location_summary": "Westwood, Kansas", "locations": [ { "city": "Westwood", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03488667" }, { "nct_id": "NCT01399684", "title": "A Study Evaluating the Efficacy and Safety of MEGF0444A Dosed to Progression in Combination With Bevacizumab and mFOLFOX-6 in Participants With Previously Untreated Metastatic Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Colorectal Cancer" ], "interventions": [ { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Folinic acid", "type": "DRUG" }, { "name": "MEGF0444A", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 127, "start_date": "2011-11", "completion_date": "2014-02", "has_results": false, "last_update_posted_date": "2016-08-26", "last_synced_at": "2026-09-13T18:15:58.778Z", "location_count": 23, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Bakersfield, California + 18 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01399684" }, { "nct_id": "NCT06258525", "title": "SAMe in Prevention of Oxaliplatin-associated Liver Injury", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Cancer", "Liver Metastases", "Liver Metastasis Colon Cancer", "Liver Injury", "Sinusoidal Obstruction Syndrome", "5-Fluorouracil Toxicity", "Liver Toxicity, Chemically-Induced" ], "interventions": [ { "name": "Standard of care oxaliplatin-based chemotherapy", "type": "RADIATION" }, { "name": "S-adenosylmethionine (SAMe) supplement", "type": "DIETARY_SUPPLEMENT" }, { "name": "Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "RADIATION", "DIETARY_SUPPLEMENT", "PROCEDURE" ], "sponsor": "Cedars-Sinai Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2026-07", "completion_date": "2028-08", "has_results": false, "last_update_posted_date": "2026-05-06", "last_synced_at": "2026-09-13T18:15:58.778Z", "location_count": 2, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06258525" }, { "nct_id": "NCT00707889", "title": "Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Colorectal Cancer", "Adenocarcinoma of the Colon", "Adenocarcinoma of the Rectum" ], "interventions": [ { "name": "ABT-869", "type": "DRUG" }, { "name": "bevacizumab", "type": "DRUG" }, { "name": "oxaliplatin", "type": "DRUG" }, { "name": "folinic acid", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie (prior sponsor, Abbott)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 159, "start_date": "2008-10", "completion_date": "2012-05", "has_results": false, "last_update_posted_date": "2013-05-15", "last_synced_at": "2026-09-13T18:15:58.778Z", "location_count": 3, "location_summary": "Chapel Hill, North Carolina • Philadelphia, Pennsylvania • Nashville, Tennessee", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00707889" } ] }